SCHEMBL31397447

SCHEMBL31397447

COC(=O)Cc1ccc(-c2cc3c(cn2)[nH]c(=O)n3C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3B Q13370 3/20 0.41
▸ PDE3A Q14432 3/20 0.41
▸ P2RY12 Q9H244 3/20 0.41
▸ PDE2A O00408 2/20 0.41
▸ HPGD P15428 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ MAOB P27338 3/20 0.40
▸ CHEK1 O14757 2/20 0.40
▸ LMNA P02545 2/20 0.39
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ CYP4F2 P78329 1/20 0.37
▸ CYP4A11 Q02928 1/20 0.37
▸ CDK2 P24941 1/20 0.37
▸ AKT1 P31749 1/20 0.37
▸ PGR P06401 1/20 0.36
▸ TLR7 Q9NYK1 1/20 0.36
▸ CYP11B1 P15538 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22493184 0.80 TSHR (0.54) PDE3BPDE3AP2RY12PDE2AHPGD
SCHEMBL31397203 0.77 PDE3B (0.47) PDE3BPDE3AP2RY12HPGDMAPT
SCHEMBL31397549 0.70 DDB1 (0.54) GCK
SCHEMBL27694530 0.69 RAB9A (0.49) HPGDMAPTLMNANPC1RAB9A
SCHEMBL13247054 0.66 LMNA (0.57) PDE3BPDE3AHPGDMAPTTSHR
SCHEMBL31397104 0.65 MAPK1 (0.39) HPGDMAPTLMNANPC1RAB9A
SCHEMBL4113212 0.65 CYP4F2 (0.76) HPGDMAPTLMNANPC1RAB9A
SCHEMBL12869882 0.65 LMNA (0.55) HPGDLMNANPC1RAB9AALDH1A1
SCHEMBL22493206 0.65 MAOB (0.50) HPGDMAPTMAOBLMNAALDH1A1
SCHEMBL25242176 0.64 MAPK8 (0.51) CYP4F2CYP4A11SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240424111-A1 Degrader Compounds and Uses Thereof CALICO LIFE SCIENCES LLC (US) 2024-12-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240424111-A1 Degrader Compounds and Uses Thereof PTPN1, PTPN2, PTPN5 PDE3B 3780/4885PDE3A 3612/4885P2RY12 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback